VFEND POWDER FOR SOLUTION

Šalis: Kanada

kalba: anglų

Šaltinis: Health Canada

Veiklioji medžiaga:

VORICONAZOLE

Prieinama:

PFIZER CANADA ULC

ATC kodas:

J02AC03

INN (Tarptautinis Pavadinimas):

VORICONAZOLE

Dozė:

200MG

Vaisto forma:

POWDER FOR SOLUTION

Sudėtis:

VORICONAZOLE 200MG

Vartojimo būdas:

INTRAVENOUS

Vienetai pakuotėje:

15G/50G

Recepto tipas:

Prescription

Gydymo sritis:

AZOLES

Produkto santrauka:

Active ingredient group (AIG) number: 0150242002; AHFS:

Autorizacija statusas:

APPROVED

Leidimo data:

2004-08-20

Prekės savybės

_Product Monograph _
_ _
_VFEND (voriconazole) _
_Page 1 of 73_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
VFEND
®
Voriconazole
Tablets 50 mg and 200 mg, Oral
200 mg / Vial (10 mg/mL when reconstituted) for Injection
Powder for Oral Suspension 3 g / Bottle (40 mg/mL when reconstituted)
Antifungal Agent
Pfizer Canada ULC
17300 Trans Canada Highway
Kirkland, Quebec
H9J 2M5
Date of Initial Authorization:
AUG 20, 2004
Date of Revision:
JUL 05, 2023
Submission Control Number: 272725
Registered trademark Pfizer Products Inc.
Pfizer Canada ULC., licensee
© Pfizer Canada ULC, 2023
_ _
_Product Monograph _
_ _
_VFEND (voriconazole) _
_Page 2 of 73_
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS, Skin
07/2023
7 WARNINGS AND PRECAUTIONS, Carcinogenesis and Mutagenesis
11/2022
7 WARNINGS AND PRECAUTIONS, Tyrosine kinase inhibitors (CYP3A4
substrates)
11/2022
2 CONTRAINDICATIONS
02/2021
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
.
RECENT MAJOR LABEL CHANGES
..........................................................................................
2
TABLE OF CONTENTS
............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................................... 4
1
INDICATIONS
.............................................................................................................
4
1.1
Pediatrics
..................................................................................................................
4
1.2
Geriatrics
..................................................................................................................
4
2
CONTRAINDICATIONS
................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
........................................................... 6
4
DOSAGE AND ADMINISTRATION
.......................